RECOVERY: World’s Largest COVID-19 Clinical Trial

RECOVERY: World’s Largest COVID-19 Clinical Trial
share Share

In the UK, the world’s largest clinical trial of potential coronavirus treatments, the Randomised Evaluation of COVID-19 Therapy trial (RECOVERY), is underway. It is aimed at assessing the effects of different treatments, including repurposed and novel drugs, on major outcomes in COVID-19.

 

You may also like: COVID-19 Will Revolutionise Imaging Practices

 

The trial began on 19 March, and has been progressing rapidly – 9 days for first protocol to first patient and 13 days to reach 500 patients, while around 1,000 patients from 132 different hospitals have enrolled in the first 15 days. Every COVID-19 patient in the UK over the age of 18 years may be invited to participate. Those having accepted are randomly allocated to standard of care alone, or standard of care plus one of the additional treatments. Specifically, randomisation will initially be to one of the following arms:

  • Usual care.
  • Usual care plus lopinavir-ritonavir (commonly used to treat HIV).
  • Usual care plus low-dose dexamethasone (a type of steroid use in a range of conditions to reduce inflammation).
  • Usual care plus hydroxychloroquine (a treatment for malaria).


The option of usual care plus inhaled interferon is yet to start. In general, the design of the study allows further medicines to be added within days after they have been identified.


The above treatments have been recommended by an expert panel advising the Chief Medical Officer for England. If any of the them is scientifically supported, it will be immediately applied to treat NHS patients. Definitive results are expected within months.


Health and Social Care Secretary Matt Hancock said this trial marked “a major milestone in our battle against coronavirus.”


The trial is being coordinated by researchers at the University of Oxford, led by Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine, and Martin Landray, Professor of Medicine and Epidemiology at the Nuffield Department of Population Health.


The study has received €2.4 million (£2.1 million) from UK Research and Innovation (UKRI) and the Department of Health and Social Care. It is part of a wider €23 million (£20 million) rapid COVID-19 research response investment by the UK government. The other two key national trials are
PRINCIPLE and REMAP-CAP.


If you want to share your experience and perspective on COVID-19,
please do.

If your company is interested in engaging with our COVID-19 community, please send us an email.


Source: UK Department of Health and Social Care

Image credit: iStock

«« Policy, Guidance and Recommendations for COVID-19 Decision-Making


EU Medical Devices Regulation is Postponed »»

Published on : Mon, 6 Apr 2020



Related Articles
Policy, Guidance and Recommendations for COVID-19 Decision-Making

The World Health Organization (WHO) continues to expand its COVID-19 resource base for policymakers and decision-makers... Read more

Exponential Growth of COVID-19 Cases in Africa

There are now more than 10,000 confirmed COVID-19 cases in Africa with over 500 deaths. Due to the rapid spread of the... Read more

Warnings about Potential Treatments for COVID-19

An early-released review warns about potentially serious adverse events for chloroquine, hydroxychloroquine and azithromycin... Read more

NHS, clinical trials, COVID-19, novel coronavirus, Nuffield Department of Medicine RECOVERY: World’s Largest COVID-19 Clinical Trial

No comment


Please login to leave a comment...